Cortexyme (CRTX) Competitors $1.60 +0.02 (+1.27%) As of 09/12/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesTrendsBuy This Stock CRTX vs. OMCL, HSTM, MDRX, PLX, IKT, IZTC, CVM, ZIVO, SRNE, and JATTShould you be buying Cortexyme stock or one of its competitors? The main competitors of Cortexyme include Omnicell (OMCL), HealthStream (HSTM), Veradigm (MDRX), Protalix BioTherapeutics (PLX), Inhibikase Therapeutics (IKT), Invizyne Technologies (IZTC), CEL-SCI (CVM), ZIVO Bioscience (ZIVO), Sorrento Therapeutics (SRNE), and JATT Acquisition (JATT). Cortexyme vs. Its Competitors Omnicell HealthStream Veradigm Protalix BioTherapeutics Inhibikase Therapeutics Invizyne Technologies CEL-SCI ZIVO Bioscience Sorrento Therapeutics JATT Acquisition Cortexyme (NASDAQ:CRTX) and Omnicell (NASDAQ:OMCL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment. Which has more volatility and risk, CRTX or OMCL? Cortexyme has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Is CRTX or OMCL more profitable? Omnicell has a net margin of 2.01% compared to Cortexyme's net margin of 0.00%. Omnicell's return on equity of 4.27% beat Cortexyme's return on equity.Company Net Margins Return on Equity Return on Assets CortexymeN/A -70.96% -63.53% Omnicell 2.01%4.27%2.44% Do institutionals and insiders have more ownership in CRTX or OMCL? 63.2% of Cortexyme shares are owned by institutional investors. Comparatively, 97.7% of Omnicell shares are owned by institutional investors. 27.9% of Cortexyme shares are owned by insiders. Comparatively, 2.5% of Omnicell shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media refer more to CRTX or OMCL? In the previous week, Omnicell had 8 more articles in the media than Cortexyme. MarketBeat recorded 8 mentions for Omnicell and 0 mentions for Cortexyme. Omnicell's average media sentiment score of 1.38 beat Cortexyme's score of 0.00 indicating that Omnicell is being referred to more favorably in the news media. Company Overall Sentiment Cortexyme Neutral Omnicell Positive Which has preferable earnings & valuation, CRTX or OMCL? Omnicell has higher revenue and earnings than Cortexyme. Cortexyme is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCortexymeN/AN/A-$89.94M-$2.97-0.54Omnicell$1.11B1.31$12.53M$0.5063.66 Do analysts prefer CRTX or OMCL? Omnicell has a consensus target price of $46.71, indicating a potential upside of 46.76%. Given Omnicell's stronger consensus rating and higher probable upside, analysts clearly believe Omnicell is more favorable than Cortexyme.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cortexyme 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Omnicell 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57 SummaryOmnicell beats Cortexyme on 13 of the 15 factors compared between the two stocks. Get Cortexyme News Delivered to You Automatically Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRTX vs. The Competition Export to ExcelMetricCortexymeBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.24M$289.72M$5.84B$10.14BDividend YieldN/AN/A5.68%4.60%P/E Ratio-0.54N/A75.4125.98Price / SalesN/A420.31515.81181.13Price / CashN/A22.4437.5660.44Price / Book0.4010.9112.156.29Net Income-$89.94M-$111.61M$3.29B$271.07M7 Day Performance-0.62%-0.50%0.73%3.87%1 Month Performance-6.98%4.64%4.99%5.49%1 Year Performance117.69%-15.57%62.53%25.86% Cortexyme Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRTXCortexymeN/A$1.60+1.3%N/A+117.7%$48.24MN/A-0.5455OMCLOmnicell3.8709 of 5 stars$32.40+0.2%$46.71+44.2%-26.3%$1.49B$1.15B64.713,670News CoveragePositive NewsHSTMHealthStream4.4396 of 5 stars$28.29+0.7%$31.00+9.6%+0.3%$838.52M$291.65M42.221,093Positive NewsMDRXVeradigm2.361 of 5 stars$4.85-0.2%$13.00+168.0%-52.6%$525.09M$1.53B0.008,000News CoveragePLXProtalix BioTherapeutics2.3289 of 5 stars$1.66+4.7%$15.00+806.3%+70.8%$131.96M$61.95M-12.73200Positive NewsIKTInhibikase Therapeutics1.4732 of 5 stars$1.62-2.4%$6.50+301.2%+32.2%$120.72MN/A-0.616Positive NewsIZTCInvizyne TechnologiesN/A$12.00+0.3%N/AN/A$75.02MN/A0.0029News CoverageCVMCEL-SCI1.3448 of 5 stars$10.29-0.6%N/A-73.3%$70.92MN/A-21.4743Positive NewsShort Interest ↓ZIVOZIVO Bioscience0.3485 of 5 stars$12.50-15.8%N/A-3.7%$47.71M$15.85K-2.5610News CoverageHigh Trading VolumeSRNESorrento Therapeutics0.9143 of 5 stars$0.07+1,994.3%N/A-22.2%$40.41M$60.32M0.00800Gap DownJATTJATT AcquisitionN/A$2.21+0.5%N/A-44.4%$38.12MN/A0.003News CoverageHigh Trading Volume Related Companies and Tools Related Companies Omnicell Alternatives HealthStream Alternatives Veradigm Alternatives Protalix BioTherapeutics Alternatives Inhibikase Therapeutics Alternatives Invizyne Technologies Alternatives CEL-SCI Alternatives ZIVO Bioscience Alternatives Sorrento Therapeutics Alternatives JATT Acquisition Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRTX) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredExpert Alert: Massive Bubble Could Crash Your WealthOn July 4th, Trump signed the “One Big Beautiful Bill,” adding $3.4 trillion to the national debt — and pushin...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredApple’s falling behindApple just posted record-breaking results, yet its stock barely moved — because in today’s market, investors o...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cortexyme, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cortexyme With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRTX Stock Alerts